Bicara Therapeutics BCAX Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's share based compensation arrangement by share based payment award fair value assumptions weighted average volatility rate.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Bicara Therapeutics's share based compensation arrangement by share based payment award fair value assumptions weighted average volatility rate?
- Bicara Therapeutics (BCAX) reported share based compensation arrangement by share based payment award fair value assumptions weighted average volatility rate of 90.8% in Q4 2024.
- What does share based compensation arrangement by share based payment award fair value assumptions weighted average volatility rate mean?
- Weighted-average volatility is a measure of the expected fluctuation in the company's stock price over the expected term of the options granted. It is a critical input in the Black-Scholes or similar valuation models for stock-based compensation. Higher volatility generally increases the fair value of options, reflecting greater uncertainty in future stock performance.